1-4 of 4
Sabrin Albeituni, PhD
Close
Sort by
Journal Articles

Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis

Eduardo Huarte, PhD, Michael Peel, PhD, Katherine Verbist, PhD, Brittany Fay, Sabrin Albeituni, PhD, Kim E. Nichols, MD, Paul Smith, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21.
https://doi.org/10.1182/blood-2020-139539
Published: 2020
Journal Articles

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Lauren K. Meyer, Katherine Verbist, PhD, Sabrin Albeituni, PhD, Rachel Bassett, Michelle L. Hermiston, MD PhD, Kim E. Nichols, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 81.
https://doi.org/10.1182/blood-2019-129112
Published: 2019
Journal Articles

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Stacey R. Dillon, PhD, Katherine E. Lewis, PhD, Katherine Verbist, PhD, Paige Tedrick, PhD, Sabrin Albeituni, PhD, Ryan Swanson, B.S., Lawrence S. Evans, B.S., Steven D Levin, PhD, Mark W. Rixon, PhD, Stanford L. Peng, MD, PhD, Kim E. Nichols, MD, Kristine M. Swiderek, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2037.
https://doi.org/10.1182/blood-2018-99-110001
Published: 2018
Journal Articles

Combined Treatment with Ruxolitinib and Dexamethasone Curtails Inflammation and Lessens Disease in Preclinical Studies of Hemophagocytic Lymphohistiocytosis

Sabrin Albeituni, PhD, Katherine Verbist, PhD, Paige Tedrick, Heather Tillman, PhD, Kim E. Nichols, MD
Journal: Blood
Blood (2016) 128 (22): 4894.
https://doi.org/10.1182/blood.V128.22.4894.4894
Published: 2016